More problems for BioNTech & Roche’s neoantigen shot
Autogene cevumeran goes on hold in adjuvant bladder cancer.
TuHura makes its bid for Merkel accelerated approval
The company reckons its immunotherapy could improve on Keytruda.
Scancell’s dilemma delayed
The group touts a 72% ORR with SCIB1, but full Scope data have been pushed back into 2025.
Gritstone has a mountain to climb with Granite
The group is persevering with Granite, but funds might be hard to come by.
Accelerated path closes for Moderna/Merck’s immunotherapy
Moderna has also canned projects targeting KRAS and Ox40L/IL-23/IL-36γ.
Interim miss slows IO Biotech
An accelerated approval looks off the table, as the group’s first-line melanoma trial continues.
